ITIL-168
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 17/100
17
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Cutaneous Melanoma
Conditions
Advanced Cutaneous Melanoma
Trial Timeline
Oct 7, 2021 → Feb 27, 2023
NCT ID
NCT05050006About ITIL-168
ITIL-168 is a phase 2 stage product being developed by Instil Bio for Advanced Cutaneous Melanoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT05050006. Target conditions include Advanced Cutaneous Melanoma.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Cutaneous Melanoma were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
12
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05393635 | Phase 1 | Withdrawn |
| NCT05050006 | Phase 2 | Terminated |
Competing Products
20 competing products in Advanced Cutaneous Melanoma